Herbalife Nutrition Ltd

Herbalife's board has approved a share repurchase program of up to US$250 million over three years, giving management room to buy back stock when it sees value. The company's shares have picked up modest near-term momentum, with a 1-day share price return of 2.6% and a 7-day share price return of 2.5%, though the year-to-date share price return is still down 4.6% even after a 35.3% total shareholder return over the past year. Herbalife is trading at $12.23 against a most-followed fair value view of $17, a gap that frames the new $250 million buyback as management acting while the market price still lags that narrative. The company continues to experience flat to declining volumes in several regions, with only modest improvements in constant currency net sales, and its ongoing reliance on network recruiting and regional distributor growth increases vulnerability to macroeconomic downturns and currency headwinds in emerging markets.

Herbalife's board approved a new $250 million share buyback on September 8, to be spread across the next three years, a vote of confidence in a stock trading in the single digits with a battered balance sheet. CFO John DeSimone framed the repurchase as a reflection of free cash flow generation and flexibility to keep investing in the business, and the second quarter, reported August 5, brought net sales of $1.3 billion, up 5.4% year over year and at the top of guidance, or 5.8% in constant currency, marking the fourth straight quarter of year-over-year sales expansion on both a reported and constant currency basis. Latin America led with net sales up 16.6%, while Asia Pacific rose 15.2%, or 23.1% at constant currency, and adjusted EBITDA of $166.6 million landed near the top of the guided range, beating guidance outright at $174.4 million in constant currency. The same quarter produced a net loss attributable to the company of $26.3 million, driven largely by a $94.6 million charge tied to extinguishing debt after an April refinancing, with gross margin slipping to 77.7% from 78.0% and adjusted EBITDA margin down 120 basis points to 12.6%, while China sales dropped 24.5% as reported and 29.0% at constant currency and EMEA fell 3.5%, or 5.6% adjusting for currency. Management narrowed full-year 2026 guidance, trimming the reported adjusted EBITDA range to $670 million to $690 million from a prior $675 million to $705 million on FX headwinds even as the constant currency outlook was raised, and DeSimone is set to retire at the end of 2026, handing the CFO role to Scott Schaefer on January 1, 2027, with the balance sheet still carrying a total shareholders' deficit of $466.9 million as of June 30 alongside more than $2 billion in long-term debt.

Herbalife Ltd. reaffirmed its third quarter and full-year 2026 financial guidance, originally provided on August 5, 2026, expecting year-over-year net sales growth for both periods on a reported and constant currency basis. The company also reaffirmed its adjusted EBITDA guidance, with third-quarter adjusted EBITDA projected between $160 million and $180 million and full-year adjusted EBITDA between $670 million and $690 million. Chief Financial Officer John DeSimone expressed confidence in delivering a fifth consecutive quarter of year-over-year net sales growth. The guidance assumptions, including foreign exchange rates, remain unchanged from the previous disclosure.

Herbalife Ltd. outlined full-year 2026 adjusted EBITDA guidance of $670 million to $690 million on a reported basis while announcing that CFO John DeSimone will retire at year-end and be succeeded by Scott Schaefer at the start of 2027. Second-quarter net sales rose 5.4% to $1.3 billion, at the top end of guidance, and adjusted EBITDA reached $167 million, also at the high end of its range. The company narrowed its full-year net sales growth outlook to 2.5% to 5.5% on both a reported and constant currency basis, and it still targets a net leverage ratio below 2x by year-end. The quarter included a GAAP net loss of $26 million driven by a nearly $95 million pretax loss on debt extinguishment, while operating cash flow for the first half of 2026 jumped 52% to $147 million. Management highlighted the launch of Bioniq Go personalized supplements and the continued beta expansion of the Pro2col platform as key strategic milestones.

A new Herbalife survey reveals that four in five consumers across Asia Pacific now consider holistic health very or extremely important, with 74% saying it matters more than three years ago. The Herbalife APAC Wellness Culture Survey 2026, which polled over 10,000 respondents in 11 markets including Australia, Hong Kong SAR, Indonesia, Japan, Korea, Malaysia, Philippines, Singapore, Taiwan region, Thailand and Vietnam, found that 44% want to improve sleep quality, 38% seek better mental wellbeing and stress management, 31% aim to enhance nutrition quality, and 30% focus on weight management. Top factors driving the trend include aging at 46%, personal health scares at 42%, growing awareness of wellness trends at 32%, and a desire to invest in long-term health at 31%. Around 58% of respondents increased both the variety and frequency of wellness activities compared to three years ago, with regular exercise, healthier food choices, improved sleep habits, and supplement use among the most common practices. Despite this progress, only two in five say their current physical, mental and emotional health is better than three years ago, citing lack of time and motivation as key challenges, while many look to family, friends, and social media for greater support.

The global advanced therapeutics market for aging and wellness is projected to grow from $154.89 billion in 2024 to $275.35 billion by 2035, at a compound annual growth rate of 5.51%. The functional nutrition segment held the largest share by product type in 2024, while energy, endurance, and active aging led among application types, and retail dominated distribution channels. North America accounted for the largest regional share, driven by a developed healthcare ecosystem and high consumer awareness. Key players include Abbott, Amway, and Nestlé, with recent developments such as Amway's 2.1 billion yuan investment plan in China and Orgain's launch of a plant-based protein powder with metabolism support.

Herbalife and IIT Madras have inaugurated India's first dedicated facility for translational research in plant cell fermentation technology. The Herbalife–IIT Madras Centre of Excellence, launched on 22nd June 2026 at IIT Madras Research Park, aims to position India as a global leader in sustainable biomanufacturing and next-generation plant-derived health and wellness products. The centre will focus on scalable production of herbal biomass, development of enriched extracts and high-value phytochemicals, and bridging the gap between lab discoveries and industrial applications. It is equipped with customized plant cell bioreactors, advanced analytical platforms, and pilot-scale processing facilities. The initiative aligns with India's BioE3 and Atmanirbhar Bharat missions and is expected to foster academia-industry collaborations, intellectual property generation, and entrepreneurship.